What is lurbinectedin used for?
Lurbinectedin (brand name Zepzelca) treats metastatic small cell lung cancer (SCLC) in adults with disease progression on or after platinum-based chemotherapy. The FDA approved it in 2020 for this second-line indication.[1]
Standard chemotherapy alternatives
Patients progressing after first-line platinum-etoposide often receive:
- Topotecan: Intravenous or oral forms approved as second-line therapy; median overall survival around 6-8 months in trials.[1][2]
- Irinotecan: Used off-label or in combinations, particularly outside the US; shows response rates of 10-20% in relapsed SCLC.[2]
- Combinations like CAV (cyclophosphamide, doxorubicin, vincristine): Older regimen with response rates up to 25% but higher toxicity.[2]
These remain first-choice alternatives due to established guidelines from NCCN and ESMO.[1]
Other approved targeted therapies and immunotherapies
- Amrubicin: Approved in Japan and used off-label; phase III trials report superior response rates (31%) vs. topotecan (17%) with similar survival.[2]
- Immune checkpoint inhibitors: Pembrolizumab or atezolizumab sometimes combined with chemo in relapsed settings, though less common post-platinum; ongoing trials explore maintenance roles.[1][3]
- Trilaciclib (Cosela): Not a direct alternative but given before chemo to protect bone marrow; FDA-approved for SCLC to reduce myelosuppression.[1]
No direct head-to-head trials compare these to lurbinectedin, but topotecan sets the benchmark (response rate ~15%, median survival 5.5 months).[2]
Emerging options and clinical trials
- Tarlatamab (Imdelltra): FDA-approved 2024 bispecific T-cell engager for advanced SCLC post-platinum; 40% response rate in trials, with rapid tumor reduction.[3]
- Tiragolumab + atezolizumab: Phase III trials ongoing for relapsed SCLC; early data show doubled progression-free survival vs. placebo.[3]
- Active trials (ClinicalTrials.gov): Include sacituzumab govitecan (Tropics-03 trial), lurbinectedin combos with atezolizumab, and CAR-T therapies. Over 100 recruiting studies target relapsed SCLC.[3]
Consult NCCN guidelines or oncologist for trial eligibility, as SCLC prognosis is poor (median survival <12 months post-relapse).[1]
How do these compare to lurbinectedin?
| Treatment | Response Rate | Median PFS | Median OS | Key Notes |
|-----------|---------------|------------|-----------|-----------|
| Lurbinectedin | 35% | 5.1 months | 11.2 months | Single-agent convenience[2] |
| Topotecan | 15-24% | 3.3 months | 6.5 months | More myelosuppression[2] |
| Tarlatamab | 40% | 4.9 months | 14.3 months | Infusion reactions common[3] |
| Amrubicin | 31% | 4.5 months | 9.2 months | Limited US access[2] |
Lurbinectedin edges topotecan in efficacy per approval trial, but tarlatamab offers higher responses for eligible patients.[2][3]
[1]: FDA.gov - Zepzelca Approval
[2]: NCCN Guidelines - SCLC v2.2024
[3]: ClinicalTrials.gov - SCLC Trials